Sign in to continue:

Sunday, July 26th, 2026

Angelalign Technology Inc. Announces EGM Poll Results for Connected Transactions and Share Schemes on July 23, 2026 1




Angelalign Technology Inc. EGM Poll Results – Key Developments for Investors

Angelalign Technology Inc. Announces Key EGM Poll Results: Multiple Resolutions Approved

Overview

Angelalign Technology Inc. (Stock code: 6699), a leading provider in the clear aligner market, has released the results of its Extraordinary General Meeting (EGM) held on July 23, 2026. Several critical resolutions were put to shareholder vote, potentially impacting the company’s strategic direction and share price.

Key Points from the EGM

  • All Resolutions Passed with Overwhelming Support: All four ordinary resolutions proposed at the EGM were approved by a significant majority, demonstrating strong shareholder confidence in the company’s direction.
  • Major Connected Transaction Approved: The continuing connected transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement were approved. This framework governs clear aligner purchases and sales between Angelalign and related parties for the next three years—an important step in securing future revenues and supply chain stability.
  • Termination of Post-IPO Share Option Scheme: Shareholders approved the termination of the existing Post-IPO Share Option Scheme. This move may signal a strategic shift in the company’s approach to employee incentives and capital management.
  • Amendments to the Post-IPO RSU Scheme: Significant amendments to the company’s Restricted Share Unit (RSU) Scheme were passed, including a refresh of the RSU Scheme Limit. This enhances the company’s ability to attract and retain talent via equity-based incentives, potentially impacting future dilution.
  • Board Authorization: The Board was granted authority to implement and execute all acts and documents necessary to give effect to the above resolutions, providing flexibility and swiftness in executing strategic initiatives.

Detailed Poll Results

Resolution For Against Approval Rate
1. 2027-2029 Clear Aligners Purchase and Sales Framework Agreement 41,890,325 600 99.99%
2. Termination of Post-IPO Share Option Scheme 129,058,725 600 99.99%
3. Amendments to Post-IPO RSU Scheme 37,353,654 4,537,271 89.17%
4. Board Authorization for Implementation 124,492,994 4,615,331 96.43%

Shareholder Participation and Voting Details

  • The company had 170,896,375 issued shares as of the EGM date, with no treasury shares or repurchased shares pending cancellation.
  • Major Shareholder Abstentions:

    • CareCapital Orthotech Limited and Noble Affluent Limited (together holding approximately 51.13% of shares) abstained from voting on the connected transaction (Resolution 1).
    • CareCapital Orthotech Limited also abstained from voting on the RSU amendments (Resolution 3).
    • Trustees of the employee incentive scheme abstained from voting with respect to 1,262,610 shares, as per regulatory requirements.
  • All other shareholders were eligible to vote, and there were no stated intentions to oppose or abstain on any resolution beyond the required abstentions.
  • All seven directors attended the EGM, either in person or electronically, ensuring full board oversight of the proceedings.
  • Tricor Investor Services Limited acted as scrutineer for the vote-taking, ensuring independent verification of results.

Potential Price-Sensitive Impacts

  • Securing Framework Agreements: Approval of the 2027-2029 framework agreement ensures business continuity and may strengthen medium-term revenue visibility.
  • Changes to Employee Incentive Schemes: The termination of the Share Option Scheme and amendments to the RSU Scheme could affect investor views on dilution, talent attraction, and cost management.
  • Strong Shareholder Support: Near-unanimous approval of all resolutions highlights robust investor confidence, which may positively influence share price sentiment.

Board and Management

  • Mr. FENG Dai continues as Chairman, with the Board comprising a mix of executive and independent non-executive directors, ensuring a balance of oversight and experience.

Conclusion

The EGM outcomes position Angelalign Technology Inc. for strengthened operations, improved governance, and enhanced strategic flexibility. Investors should monitor future disclosures regarding the implementation of these resolutions, as they may affect the company’s growth trajectory and capital structure.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professionals before making investment decisions. The company’s future performance may be affected by the execution of these resolutions and other market factors.




View ANGELALIGN Historical chart here



Ascentage Pharma Announces Trustee Purchase of Shares for 2022 RSU Scheme on June 11, 2026

Ascentage Pharma Group International Announces Trustee Purch...